Role of *Lactobacillus* in cervical cancer

Xi Yang1
Miao Da2
Wenyuan Zhang3
Quan Qi4
Chun Zhang5
Shuwen Han4

1Department of Intervention and Radiotherapy, Huzhou Central Hospital, 2Medical College of Nursing, Huzhou University, 3Department of Gynaecology, 4Department of Medical Oncology, 5Department of Infectious Diseases, Huzhou Central Hospital, Huzhou, Zhejiang Province, People’s Republic of China

Correspondence: Shuwen Han
Department of Medical Oncology, Huzhou Central Hospital, No 198 Hongqi Road, Huzhou, Zhejiang Province 313000, People’s Republic of China
Tel +86 572 202 3301
Email shuwenhan985@163.com

Abstract: Cervical cancer is a common malignant cancer among women worldwide. Changes in the vaginal microecological environment lead to multiple gynecological diseases, including cervical cancer. Recent research has shown that *Lactobacillus* may play an important role in the occurrence and development of cervical cancer. This review explores the role of *Lactobacillus* in cervical cancer. A total of 29 articles were included after identification and screening. The pertinent literature on *Lactobacillus* in cervical cancer from two perspectives, including clinical studies and experimental studies, was analyzed. An association network for the mechanism by which *Lactobacillus* induces cervical cancer was constructed. In addition, we provide direction and insight for further research on the role of *Lactobacillus* in cervical cancer.

Keywords: CIN, cervical cancer, *Lactobacillus*, microorganism

Introduction

Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths among women worldwide.1–2 Epidemiological investigations have shown that the number of new cases of cervical cancer per year is ~485,000, with 236,000 deaths occurring per year globally.3 Patients with cervical cancer often exhibit no obvious symptoms and signs at early stages; thus, the disease tends to be ignored and is easily misdiagnosed. Cervical cytologic screening has generally been used to detect cervical cancer and premalignant lesions over the past decade, and early diagnosis and appropriate treatment reduce the risk of cancer-related death.4

Current research has shown that microorganisms may play an important role in the occurrence and development of cervical cancer.5 Persistent infection with high-risk human papillomavirus (HR-HPV) is now believed to be a major causal factor in the development of the disease.6 The bacteria in the vagina maintain a dynamic balance under physiological conditions, but the imbalance of vaginal flora leads to multiple gynecological diseases, such as coleitis, high-grade cervical intraepithelial neoplasia (CIN), and cervical cancer.7 It has been confirmed that *Gardnerella* and *Monilia* are the main bacteria that induce coleitis.8,9 Previous research has shown that the abundance of vaginal flora such as *Mycoplasma genitalium*,10 aerobic lactobacilli, *Staphylococcus epidermidis*, Enterococci, *Escherichia coli*, and *Bacteriodes* species11 in patients with cervical cancer is different from that in healthy controls. However, the relationship between vaginal flora and cervical cancer has not yet been elucidated.

*Lactobacillus* is a group of bacteria that can act as a catalyst to produce lactic acid during the process of glycolysis.12 This group is the predominant bacteria in the healthy vagina and plays an important role in the protection of the female reproduction.
system.15 Summarizing previous studies, Lactobacillus in the vagina exerts its protective functions mainly through the following four potential mechanisms: 1) By preventing pathogenic bacteria from adhering to the epithelial tissue: vaginal epithelial cells (VECs) of fertile woman encounter periodic changes including hyperplasia, peeling, and repair under the effect of estrogen and progestin. Free glycogen that is produced during this process supplies matter and energy for the growth of Lactobacillus. Lactobacillus is adsorbed and occupies the VECs, and these bacteria can prevent the conglutination of invasive pathogenic bacteria that induce malignant tumors.14–16 2) By secreting organic acid: Lactobacillus produces organic acid by decomposing glucogen to maintain the vaginal acidic environment,17 which can inhibit the growth and resist the invasion of pathogenic bacteria. In addition, the vaginal acidic environment is beneficial to maintain the activity of bacteriocins and H₂O₂.18 3) By secreting various metabolites: exopolysaccharides (EPSs), phosphorylated polysaccharides, and peptidoglycans, which are secreted by Lactobacillus, can inhibit the proliferation of malignant tumors.19,20 Bacteriocin and surface-active components can inhibit the production of tumorigenic substances and the growth of harmful microorganisms.21 H₂O₂, which is also secreted by Lactobacillus, can directly kill harmful microorganisms or act in a bactericidal manner though the peroxidase-hydrogen peroxide-halide bactericidal system.18 4) By activating the immune system: Lactobacillus affects cellular and humoral immunity. On one hand, these bacteria can increase the proliferation and differentiation of thymus-derived cells (T cells).22 On the other hand, Lactobacillus, as an immune sensitizer, can increase immunological recognition and proliferation of bone marrow-derived cell (B cells).23 Lactobacillus also produces nitric oxide (NO) by stimulating macrophages and disrupting the energy metabolism of cancer cells.24 Considering the importance of lactobacilli in cervical cancer, in this review, we comprehensively analyzed and classified the pertinent literature on lactobacilli in cervical cancer from two perspectives, clinical case investigations, and studies of molecular mechanisms. We also provide direction and insight for further research on intestinal flora in cervical cancer.

Methods
The databases PubMed, Embase, and Cochrane were searched for literature published up to January 10, 2018. To achieve maximum sensitivity of the search strategy and identify all studies, the following terms were combined: (“cervix uterus” or “neck of uterus” or “uterine neck” or “cervical” or “cervix” or “uterine cervical” or “uterine cervix”) and (“neoplasms” or “tumor” or “carcinoma” or “cancer” or “intraepithelial neoplasia” or “intraepithelial neoplasms”) and (“lactic acid bacteria” or “lactobacillus” or “lactobacilli” or “vagina/vaginal flora” or “vagina/vaginal microflora” or “vagina/vaginal microorganism” or “vagina/vaginal microbiome” or “vagina/vaginal microbiota” or “vagina/vaginal microbe” or “vagina/vaginal microbiology” or “vagina/vaginal bacteria” or “vagina/vaginal bacterium”). All relevant abstracts were independently retrieved by two authors, and the articles with available information for the present systematic review were fully reviewed. A total of 29 articles were included after identification and screening. The detailed search strategy is presented in Figure 1.

Study selection
Studies adhering to the following criteria were considered for inclusion: 1) those published in English and 2) those involving Lactobacillus in CIN or cervical cancer in vivo or in vitro. The exclusion criteria were as follows: 1) letters, case reports, reviews, or conference reports; 2) the main studies not focused on the topic of vaginal Lactobacillus in CIN or cervical cancer; and 3) correlation clinical studies with a low quality score according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method.25

Results
CIN, which is considered to be a precancerous lesion of the cervix,26 was included in the present study. After identification, screening, and validation, we identified a total of 29 pertinent studies related to Lactobacillus and several of its subgenera in cervical cancer and precancerous lesions of the cervix published in recent years. The 29 pertinent studies were divided into two groups that comprised 14 clinical studies in one group and 15 experimental studies in the other group. The clinical studies and experimental studies are shown in Tables 1 and 2, respectively.

As shown in Table 1, 16S rRNA gene sequencing was the main method used to detect microbial community structure and relative abundance. The presence of cervical cancer and precancerous lesions in women was associated with a high relative abundance of Lactobacillus iners and Lactobacillus sp and low relative abundance of Lactobacillus jensenii and Lactobacillus crispatus. Two investigations revealed that the abundance of Lactobacillus in women with human papillomavirus (HPV) infection was lower (panel numbers 6 and 10). A randomized, double-blind, placebo-controlled study...
Role of Lactobacillus in cervical cancer

showed that an oral lactobacilli (panel number 11) and an HR-HPV E7-expressing Lactobacillus-based vaccine (panel number 8) were able to decrease the risk of CIN. Moreover, two randomized controlled trial studies (panel numbers 12 and 13) supported the hypothesis that LC9018 (a biological response modifier prepared from heat-killed Lactobacillus casei YTT9018) was able to protect patients from radiation-induced leukopenia with few side effects.

As shown in Table 2, cancer cell and animal models were used along with molecular biology techniques such as the cell counting kit-8 assay, Western blots, immunohistochemistry, polymerase chain reaction, and enzyme-linked immunosorbent assays to study the role of Lactobacillus and several subgenera in cervical cancer. The results showed that Lactobacillus, its subgenera, and their supernatants exhibited antimetastatic and antiproliferative activities in cervical cancer cell lines by regulating cancer-related genes and eliciting an immunological response. Lactobacillus inhibited the viability of cervical cancer cells through regulating HPV oncogenes (panel numbers 1 and 6), and HPV-type 16 E7 protein displayed on lactobacillus could protect against HPV-induced tumors through regulating cellular immunity (panel numbers 10–14). In particular, a negative result showed that L. casei extract was not able to inhibit the viability of cervical cancer cells in vitro (panel number 7).

As shown in Figure 2, a network of the mechanisms of Lactobacillus in cervical cancer was constructed to better visualize the theory behind the experimental studies.

Discussion

The vaginal microecological balance is dynamic and relative, and patients are able to recover from slight vaginal dysbacteriosis. The persistence of vaginal dysbacteriosis is thought to promote gynecological cancer. A decline in the quantity and activity of Lactobacillus leads to an overgrowth of anaerobic bacteria. Deleterious metabolites such as nitrous acid can be produced by these organisms, and the risk of HPV infection also increases. Persistent infection of oncogenic HPV is a cause of cervical cancer. The abundance of Lactobacillus in HPV infection is lower, and HPV oncogenes may be involved in regulation of the viability of cervical cancer cells inhibited by Lactobacillus. CIN, precancerous lesions of the cervix, is much more likely to occur with dysbacteriosis. Thus, the regulation and control of Lactobacillus may block the progression of cervical cancer.

The present study attempts to clarify the cross-talk between Lactobacillus and cervical cancer using both clinical and experimental studies by reviewing the pertinent literature. Experimental study can lay an important foundation for

Figure 1 Literature search strategy.
Notes: Databases including PubMed, Embase, and Cochrane were searched for literature published up to January 10, 2018. A total of 29 studies including 17 clinical studies and 14 experimental studies were included after identification and screening.
Abbreviation: CIN, cervical intraepithelial neoplasia.
## Table 1 Clinical studies of *Lactobacillus* in cervical cancer

<table>
<thead>
<tr>
<th>Number</th>
<th>Year</th>
<th>Authors</th>
<th>Number of women enrolled</th>
<th>Race or region</th>
<th>Subgenera of <em>Lactobacillus</em></th>
<th>Methods</th>
<th>Diseases</th>
<th>Findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2016</td>
<td>Piyathilake et al</td>
<td>Patients with CIN1 (n=90), CIN2 (n=208), and CIN3 (n=132)</td>
<td>Birmingham, AL, USA</td>
<td>Lactobacillus reuteri and several sub-genus level</td>
<td>16S rRNA sequencing</td>
<td>CIN</td>
<td>The cervical mucosal CT dominated by <em>L. iners</em> and unclassified <em>Lactobacillus</em> spp was associated with CIN2+ (OR = 3.48; 95% CI, 1.27–9.55).</td>
<td>45</td>
</tr>
<tr>
<td>2</td>
<td>2016</td>
<td>Seo et al</td>
<td>Patients with CIN (n=65) and control (n=72)</td>
<td>South Korea</td>
<td><em>L. crispatus</em> and <em>L. iners</em></td>
<td>16S rRNA gene sequencing; a food-frequency questionnaire and multivariable logistic regression analysis</td>
<td>CIN</td>
<td>Diet characterized by <em>L. iners</em>-dominant type had a higher risk of CIN, compared with the <em>L. crispatus</em>-dominant type</td>
<td>46</td>
</tr>
<tr>
<td>3</td>
<td>2015</td>
<td>Mitra et al</td>
<td>Control (n=20), LSIL (n=52), HSIL (n=92), and cervical cancer (n=5).</td>
<td>Caucasian, Asian, and Black</td>
<td><em>L. jensenii</em></td>
<td>16S rRNA gene sequencing</td>
<td>LSIL, HSIL, and ICC</td>
<td>Increasing disease severity was associated with decreasing relative abundance of <em>Lactobacillus</em> spp. The vaginal microbiome in HSIL was characterized by lower levels of <em>L. jensenii</em> (P&lt;0.01) compared to LSIL. A predominance of <em>L. iners</em> with a concomitant paucity of <em>L. crispatus</em> in the cervical microbiota was associated with CIN risk</td>
<td>47</td>
</tr>
<tr>
<td>4</td>
<td>2015</td>
<td>Oh et al</td>
<td>Women (n=70) and control (n=50)</td>
<td>South Korea</td>
<td><em>L. iners</em> and <em>L. crispatus</em></td>
<td>16S rRNA gene sequencing</td>
<td>CIN</td>
<td>Women with CIN have a more diverse <em>Lactobacillus</em> depleted vaginal microbiome, compared to normal women</td>
<td>48</td>
</tr>
<tr>
<td>5</td>
<td>2015</td>
<td>Mitra et al</td>
<td>Control (n=20), LSIL (n=52), HSIL (n=92), and cancer (n=5).</td>
<td>Caucasian, Asian, and Black.</td>
<td>Lactobacillus</td>
<td>16S rRNA gene sequencing</td>
<td>CIN</td>
<td><em>Lactobacillus</em> spp are the predominant bacteria in the healthy cervix. HPV negative women but there is low abundance of <em>lactobacillus</em> in women with LSIL. HPV (+) <em>Lactobacillus</em> sp was risk factor associated with evolution from intraepithelial lesion and invasive neoplasia</td>
<td>49</td>
</tr>
<tr>
<td>6</td>
<td>2015</td>
<td>Kwasniewski Wojciech et al</td>
<td>Women</td>
<td>European</td>
<td>Lactobacillus</td>
<td>16S rRNA gene sequencing</td>
<td>LSIL and HSIL</td>
<td><em>Lactobacillus</em> sp is the predominant bacteria in the healthy cervix. HPV negative women but there is low abundance of <em>lactobacillus</em> in women with LSIL. HPV (+) <em>Lactobacillus</em> sp was risk factor associated with evolution from intraepithelial lesion and invasive neoplasia</td>
<td>50</td>
</tr>
<tr>
<td>7</td>
<td>2014</td>
<td>Silva et al</td>
<td>Patients with evolution (214) and without evolution (n=1970)</td>
<td>Brazilian; Gynecology and Obstetrics Department at a public tertiary-level university hospital between 1995 and 2000</td>
<td>Lactobacillus sp</td>
<td>Retrospective study and multivariable logistic regression analysis</td>
<td>Intraepithelial lesions; cervical cancer</td>
<td>Oral administration of an E7-expressing <em>Lactobacillus</em>-based vaccine can elicit E7-specific mucosal immunity in the cervix of CIN3 patients</td>
<td>51</td>
</tr>
<tr>
<td>8</td>
<td>2014</td>
<td>Kawana et al</td>
<td>Patients with CIN3 (n=17)</td>
<td>Japanese women; Japan</td>
<td><em>Lactobacillus casei</em></td>
<td>ELISPOT assay</td>
<td>CIN</td>
<td>Oral administration of an E7-expressing <em>Lactobacillus</em>-based vaccine can elicit E7-specific mucosal immunity in the cervix of CIN3 patients</td>
<td>52</td>
</tr>
<tr>
<td>Year</td>
<td>Authors</td>
<td>Study Design</td>
<td>Participants</td>
<td>Intervention</td>
<td>Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Rocha et al</td>
<td>Patients with preneoplastic and neoplastic cervical uterine lesions (n=625)</td>
<td>Public health care services in Divinopolis county, Minas Gerais state, Brazil</td>
<td>Lactobacillus PCR</td>
<td>Preneoplastic and neoplastic cervical uterine lesions Lactobacillus sp was the most frequent microorganism (65%) in the patients with preneoplastic and neoplastic cervical uterine lesions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Dareng et al</td>
<td>Women (n=278)</td>
<td>Nigerian; Abuja, Nigeria</td>
<td>Lactobacillus 16S rDNA gene sequencing, Roche Linear Array(R) HPV genotyping test and logistic regression models</td>
<td>Women with or without HR-HPV infection Low relative abundance of Lactobacillus spp is in 50% of HPV infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>Ou et al</td>
<td>Women were randomized to oral lactobacilli (n=40) and oral placebo (n=40)</td>
<td>Chinese; Taiwan, China</td>
<td>Lactobacilli HPV test, pap smear, and vaginal gram stain; randomized, double-blind, placebo-controlled study</td>
<td>High-risk HPV infection; CIN Comparing with women in oral lactobacilli group, women in the placebo group had a significant higher percentage of subsequent CIN lesion during follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1993</td>
<td>Okawa et al</td>
<td>Patients with stage IIB cervical cancer (n=228)</td>
<td>Spanish; 50 institutions, Spain</td>
<td>Lactobacillus casei Randomized controlled trial</td>
<td>Cervical cancer of stage IIB LC9018 (a biological response modifier prepared from heat-killed Lactobacillus casei YTT9018) could protect the patients from radiation-induced leukopenia during radiotherapy with few side effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989</td>
<td>Okawa et al</td>
<td>Patients with stage IIB or III cervical cancer (n=61)</td>
<td>Japanese; Department of Radiology, Tokyo Women's Medical College, Tokyo, Japan</td>
<td>Lactobacillus casei Randomized controlled trial</td>
<td>Cervical cancer of stage IIB or III LC9018 enhanced the therapeutic effect of the irradiation. LC9018 could protect the patients from leukopenia during radiotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1978</td>
<td>Mead</td>
<td>Patients with invasive cervical cancer (n=21)</td>
<td>American; Department of Obstetrics and Gynecology at the University of Vermont College of Medicine, Burlington, VT, USA</td>
<td>Aerobic lactobacilli Bacteria isolation and purification</td>
<td>Cervical cancer Patients with cervical cancer have a decreased frequency of isolation of aerobic lactobacilli</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Cervical cancer and precancerous lesions in women were associated with high relative abundance of Lactobacillus and several of its subgenera. Oral lactobacilli (panel number 11) and an E7-expressing Lactobacillus-based vaccine (panel number 8) were able to decrease the risk of CIN. LC9018 protected patients from radiation-induced leukopenia with few side effects.

**Abbreviations:** CCK-8, cell counting kit-8; CIN, cervical intraepithelial neoplasia; CT, community type; HPV, human papillomavirus; HR-HPV, high-risk HPV; HSIL, high-grade squamous intraepithelial lesion; ICC, invasive cervical cancer; L. crispatus, Lactobacillus crispatus; L. iners, Lactobacillus iners; L. jensenii, Lactobacillus jensenii; LSIL, low-grade squamous intraepithelial lesion; PCR, polymerase chain reaction.
<table>
<thead>
<tr>
<th>Number</th>
<th>Year</th>
<th>Authors</th>
<th>Experimental animal and cell model</th>
<th>Subgenera of Lactobacillus</th>
<th>Methods</th>
<th>Diseases</th>
<th>Findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2017</td>
<td>Wang et al</td>
<td>CaSki cells</td>
<td>L. crispatus, L. jensenii, and L. gasseri</td>
<td>MTT assay, flow cytometry, and PCR</td>
<td>Cervical cancer</td>
<td>Supernatants of L. crispatus, L. jensenii, and L. gasseri have inhibitory effects on the viability of cervical cancer cells via regulation of HPV oncogenes and cell cycle-related genes</td>
<td>43</td>
</tr>
<tr>
<td>2</td>
<td>2017</td>
<td>Li et al</td>
<td>HeLa and U14 cell lines and Xenograft mouse</td>
<td>Lactobacilli</td>
<td>CCK-8, Western blot, and immunohistochemistry</td>
<td>Cervical cancer</td>
<td>Lactobacilli inhibit the migratory ability of cervical cancer cells and the upregulation of E-cadherin may be involved in the molecule mechanism</td>
<td>58</td>
</tr>
<tr>
<td>3</td>
<td>2017</td>
<td>Sungur et al</td>
<td>Women, cervical cancer cell, and Caco-2 cell lines</td>
<td>L. gasseri strains</td>
<td>HPLC, WST-1 cell proliferation assay, ELISA, and PCR</td>
<td>Cervical cancer</td>
<td>EPSs of L. gasseri strains isolated from human vagina induce apoptosis in HeLa cells by associating with an upregulation of Bax and Caspase 3</td>
<td>44</td>
</tr>
<tr>
<td>4</td>
<td>2017</td>
<td>Jang et al</td>
<td>Th17 cells and HeLa cell lines</td>
<td>Lactobacillus rhamnosus HN001 (L1) and Lactobacillus acidophilus La-14 (L2)</td>
<td>Enzyme-linked immunospot assay, immunoblotting, PCR, and flow cytometry</td>
<td>Cervical cancer</td>
<td>Lactobacillus rhamnosus HN001 (L1) and Lactobacillus acidophilus La-14 (L2) inhibited the adherence of Gardnerella vaginalis to cervical cancer cells</td>
<td>59</td>
</tr>
<tr>
<td>5</td>
<td>2016</td>
<td>Nouri et al</td>
<td>HeLa cell lines</td>
<td>LRS and LCS</td>
<td>MTT assay and PCR</td>
<td>Cervical cancer</td>
<td>LRS and LCS have antimetastatic and antiproliferative activities on HeLa cell lines</td>
<td>60</td>
</tr>
<tr>
<td>6</td>
<td>2016</td>
<td>Motevaseli et al</td>
<td>HeLa cells</td>
<td>L. crispatus and Lactobacillus rhamnosus</td>
<td>PCR</td>
<td>Cervical cancer</td>
<td>L. crispatus and Lactobacillus rhamnosus culture supernatants can decrease the expression of ATG14 and BECN1 as well as the HPV E6 oncogene in HeLa cells</td>
<td>61</td>
</tr>
<tr>
<td>7</td>
<td>2015</td>
<td>Kim et al</td>
<td>CaSki and HeLa cell lines</td>
<td>Lactobacillus casei</td>
<td>Flow cytometry</td>
<td>Cervical cancer</td>
<td>Lactobacillus casei extract cannot inhibit the viability of cervical cancer cells or the growth of cancer cells in the presence of anticancer drugs in vitro</td>
<td>62</td>
</tr>
<tr>
<td>8</td>
<td>2014</td>
<td>Nami et al</td>
<td>Women; HeLa cell lines and HUVEC normal cells</td>
<td>Lactobacillus plantarum</td>
<td>16S rDNA gene sequencing, disk diffusion antibiotic susceptibility test, MTT assay, DAPI staining method, and flow cytometry</td>
<td>Cervical cancer</td>
<td>Lactobacillus plantarum SBL, which is isolated from vaginal secretions of adolescent and young adult women, exhibits desirable probiotic properties and remarkable anticancer activity against the HeLa cell lines with no significant cytotoxic effects on HUVEC normal cells</td>
<td>63</td>
</tr>
<tr>
<td>9</td>
<td>2013</td>
<td>Motevaseli et al</td>
<td>Human normal fibroblast-like cervical (normal cervical) and HeLa (cervical tumor) cells</td>
<td>L. gasseri and L. crispatus</td>
<td>MTT assay, Trypan blue staining, lactate dehydrogenase assay, colorimetric caspase-3 activity assay, and PCR</td>
<td>Cervical cancer</td>
<td>L. gasseri and L. crispatus exert cytotoxic effects on cervical tumor cells and this cytotoxicity is independent of pH and lactate</td>
<td>64</td>
</tr>
<tr>
<td>10</td>
<td>2013</td>
<td>Ribelles et al</td>
<td>Mice, inbred C57BL</td>
<td>Lactococcus lactis and L. casei</td>
<td>Cell surface display techniques</td>
<td>Cervical cancer</td>
<td>E7-expressing LAB, as a mucosal live vaccine, protects against HPV-type 16-induced tumors in mice</td>
<td>65</td>
</tr>
<tr>
<td>11</td>
<td>2010</td>
<td>Lee et al</td>
<td>Mice</td>
<td>L. casei</td>
<td>Enzyme-linked immunospot assay</td>
<td>Cervical cancer</td>
<td>Oral L. casei bearing the surface-displayed E6 protein induces T-cell-mediated cellular immunity and antitumor effects in mice</td>
<td>22</td>
</tr>
</tbody>
</table>
Role of Lactobacillus in cervical cancer

<table>
<thead>
<tr>
<th>Year</th>
<th>Authors</th>
<th>Cell Line</th>
<th>Species</th>
<th>Flow/Culture</th>
<th>Cancer</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Adachi et al</td>
<td>C57BL/6 mice</td>
<td>L. casei</td>
<td>Flow cytometry</td>
<td>Cervical cancer</td>
<td>L. casei-Pro5A-E7 (HPV-type 16 E7 protein displayed on lactobacillus) can improve T cells with specific mucosal E7-type I immune responses and induce mucosal cytotoxic cellular immune responses</td>
</tr>
<tr>
<td>2006</td>
<td>Poo et al</td>
<td>Mice</td>
<td>L. casei</td>
<td>Flow cytometry, Western blot, flow cytometry, and immunofluorescence microscopy</td>
<td>Cervical cancer</td>
<td>Oral administration of L. casei-Pro5A-E7 (HPV-type 16 E7 protein displayed on lactobacillus) induces E7-specific antitumor effects in C57BL/6 mice</td>
</tr>
<tr>
<td>2006</td>
<td>Aires et al</td>
<td>Mice</td>
<td>L. casei</td>
<td>Western blot, electron microscopy analysis, immunofluorescence, immunosorbent assay, and enzyme-linked immunosorbent assay</td>
<td>Cervical cancer</td>
<td>HPV-type 16 L1 virus-like particles by recombinant L. casei cells are the promising vaccine against HPV-16 infection</td>
</tr>
<tr>
<td>1999</td>
<td>McNicol et al</td>
<td>CaSki carcinoma cell line</td>
<td>Lactobacillus acidophilus</td>
<td>PCR and quantitative culture</td>
<td>CIN; HPV 16 infection</td>
<td>Isolation of Lactobacillus sp (P=0.05) is associated with low-grade CIN or normal histology</td>
</tr>
</tbody>
</table>

**Notes:** Cancer cell and animal models and molecular biology techniques were used to study the role of Lactobacillus and several of its subgenera in cervical cancer. Lactobacillus, several subgenera, and their supernatants had antimetastatic and antiproliferative effects in cervical cancer cell lines by regulating cancer-related genes and eliciting an immunological response.

**Abbreviations:** DAPI, 4',6-diamidino-2-phenylindole; ELISA, enzyme-linked immunosorbent assay; EPSs, exopolysaccharides; HPV, human papillomavirus; L. casei, Lactobacillus casei; L. crispatus, Lactobacillus crispatus; L. gasseri, Lactobacillus gasseri; L. jensenii, Lactobacillus jensenii; LAB, lactic acid bacteria; LCS, L. crispatus supernatant; LRS, Lactobacillus rhamnosus supernatant.

Further clinical studies and clinical studies can be the reliable test of experimental study. Lactobacillus can be used as an oral probiotics in clinical practice. The signal peptide of S-layer of monolayer in the extracellular matrix (ECM) of cells is a valid vector for the extracellular matrix. The use of Lactobacillus as a vector can achieve higher expression rates in the clinical practice. The signal peptide of S-layer of monolayer in the extracellular matrix (ECM) of cells is a valid vector for the extracellular matrix. The use of Lactobacillus as a vector can achieve higher expression rates in the clinical practice.
and 4) *Lactobacillus* can selectively locate to solid cancers and can be used as a vector for gene therapy and targeted therapies.35

The diagnosis and treatment of cervical cancer have been advanced considerably in recent years, but there is still a long way to go in regard to cancer prevention. This review cannot include some unpublished research or ongoing studies. There is also a lack of large-scale multicenter clinical trials and clinical prospective cohort studies in the literature. A perfect theory cannot be constructed for the mechanism of action of *Lactobacillus* in cervical cancer. Vaginal *Lactobacillus* and its metabolites may provide a novel insight into the prevention of cervical cancer. Thus, we put forth some future directions for further study.

**Future directions**

**Elucidate the role of vaginal *Lactobacillus* in cervical cancer**

*Lactobacillus* is the dominant bacteria in the vagina and affects the growth of other bacteria.32 There appears to be a complex relationship between cervical cancer and vaginal *Lactobacillus*. However, many problems deserve further consideration. How do the community structure and diversity of *Lactobacillus* vary with differences in race, region, lifestyle, and diet? How does *Lactobacillus* drive the occurrence and development of cervical cancer? What is the role of *Lactobacillus* metabolites in balancing vaginal microecology and the development of cervical cancer?
Elucidate the immunological functions mediated by vaginal Lactobacillus in cervical cancer

Immunotherapy provides a broad perspective for the treatment of cancers. Vaginal Lactobacillus and its metabolites do affect the immune system in cervical cancer.22 Though much effort has been made into understanding the mechanisms of this effect, many bottlenecks must be addressed before stepping from the imbalanced vaginal microbiological system to the immune system to cervical cancer genesis and development. Lactobacillus is an easily available probiotic that is safe and has no side effects or toxicity. The envelope of Lactobacillus is often used as a carrier to express an alternative antigen for vaccines, which may provide a novel idea for the primary prevention of cervical cancer. A cervical cancer vaccine based on Lactobacillus with an HPV vaccine promises to be a new method for the prevention of cervical cancer. Prospective studies on cervical cancer incidence after intervention with the Lactobacillus vaccine should be performed.

Elucidate the molecular mechanism by which Lactobacillus inhibits cervical cancer

Lactobacillus inhibits the proliferation of cells from multiple cancer types. Most studies have focused on the relationship between Lactobacillus and cancer, but the mechanisms underlying this relationship have yet to be clarified. Many enzymes and peptides and the lactic acid secreted by Lactobacillus are involved in activating and regulating important signaling molecules and pathways in cervical cancer.43 It is necessary to elucidate the specific molecular mechanism or construct the molecular regulatory network in future research. Lactobacillus acts as a valuable cloning vector and is currently mainly used as a plasmid vector for the experimental research of cancer in vitro. This use may suggest additional therapeutic use as a carrier to express anticancerous or encapsulated anticancer organ in cervical cancer.

In light of the importance of Lactobacillus in cervical cancer, much attention has been paid to the study of vaginal microecology in recent years. Lactobacillus has shown tremendous promise for the prevention and treatment of cervical cancer. However, knowledge of vaginal microecology and Lactobacillus is far from complete. More research will be required before clinical application of Lactobacillus in cervical cancer is achieved.


21. Yang et al. did not specify any references.


34. Rasouli BS, Ghadimi-Darsajini A, Nekouian R, Iragian GR. In vitro anticancer activity of probiotic *Lactobacillus crispatus* are able to strongly inhibit Candida albicans growth, hyphal formation and regulate virulence-related gene expressions. *Front Microbiol*. 2017;8:564.


36. Yang et al. did not specify any references.


46. Yang et al. did not specify any references.


55. Xu YC, Lin H Randomized, double-blind, placebo-controlled study of oral lactobacilli to facilitate the clearance of genital high risk HPV infection in women. *Int J Gynecol Cancer*. 2012;141(22):6965.


